Skip to main content
SpringerLink
Log in
Book cover

Pediatric Inflammatory Bowel Disease pp 511–519Cite as

Treatment of Acute Severe Ulcerative Colitis

  • Chapter
  • First Online:

  • 616 Accesses

Abstract

Acute severe exacerbations of ulcerative colitis (ASC) are relatively rare but serious events in children. ASC can occur in patients with new onset or established disease. Children with ASC should be hospitalized and reevaluated frequently to assess for response to treatment and for potential complications. Contributing infections should be ruled out. Currently, intravenous corticosteroids remain the first-line treatment for most children with ASC. Response to corticosteroids should be monitored closely, and the Pediatric Ulcerative Colitis Activity Index (PUCAI) should be measured daily. A PUCAI score >45 on day 3 should prompt discussion and planning for second-line rescue therapy. A PUCAI score >65 on day 5 should prompt initiation of second-line therapy. Infliximab and calcineurin inhibitors effectively reduce the need for colectomy before discharge. Infliximab can be used to maintain and prolong remission, while calcineurin inhibitors are generally used for 3–6 months as a bridge to another maintenance therapy. Sequential rescue therapy is not currently recommended. Surgical indications in ASC include perforation, toxic megacolon, massive hemorrhage, or failure to respond to maximal medical management. If needed, restorative proctocolectomy is the surgery of choice.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Van Limbergen J, Russell RK, Drummond HE, Aldhous MC, Round NK, Nimmo ER, et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology. 2008;135(4):1114–22.

    PubMed  Google Scholar 

  2. Jakobsen C, Bartek J Jr, Wewer V, Vind I, Munkholm P, Groen R, et al. Differences in phenotype and disease course in adult and paediatric inflammatory bowel disease—a population-based study. Aliment Pharmacol Ther. 2011;34(10):1217–24.

    CAS  PubMed  Google Scholar 

  3. Travis SP, Stange EF, Lémann M, Oresland T, Bemelman WA, Chowers Y, et al. European Crohn’s and Colitis Organisation (ECCO). European evidence-based Consensus on the management of ulcerative colitis: current management. J Crohns Colitis. 2008;2(1):24–62.

    CAS  PubMed  Google Scholar 

  4. Turner D, Otley AR, Mack D, Hyams J, de Bruijne J, Uusoue K, et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology. 2007;133(2):423–32.

    PubMed  Google Scholar 

  5. Turner D, Hyams J, Markowitz J, Lerer T, Mack DR, Evans J, et al. Pediatric IBD Collaborative Research Group. Appraisal of the pediatric ulcerative colitis activity index (PUCAI). Inflamm Bowel Dis. 2009;15(8):1218–23.

    PubMed  Google Scholar 

  6. Turner D, Mack D, Leleiko N, Walters TD, Uusoue K, Leach ST, et al. Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response. Gastroenterology. 2010;138(7):2282–91.

    CAS  PubMed  Google Scholar 

  7. Travis SP, Farrant JM, Ricketts C, Nolan DJ, Mortensen NM, et al. Predicting outcome in severe ulcerative colitis. Gut. 1996;38(6):905–10.

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Benchimol EI, Turner D, Mann EH, Thomas KE, Gomes T, McLernon RA, et al. Toxic megacolon in children with inflammatory bowel disease: clinical and radiographic characteristics. Am J Gastroenterol. 2008;103(6):1524–31.

    PubMed  Google Scholar 

  9. Turner D, Travis SP, Griffiths AM, Ruemmele FM, Levine A, Benchimol EI, et al. European Crohn’s and Colitis Organization; Porto IBD Working Group, European Society of Pediatric Gastroenterology, Hepatology, and Nutrition. Consensus for managing acute severe ulcerative colitis in children: a systematic review and joint statement from ECCO, ESPGHAN, and the Porto IBD Working Group of ESPGHAN. Am J Gastroenterol. 2011;106(4):574–88.

    CAS  PubMed  Google Scholar 

  10. Turner D, Walsh CM, Benchimol EI, Mann EH, Thomas KE, Chow C, et al. Severe paediatric ulcerative colitis: incidence, outcomes and optimal timing for second-line therapy. Gut. 2008;57(3):331–8.

    CAS  PubMed  Google Scholar 

  11. Bolia R, Rajanayagam J, Hardikar W, Alex G. Impact of changing treatment strategies on outcomes in pediatric ulcerative colitis. Inflamm Bowel Dis. 2019;25(11):1838–44. https://doi.org/10.1093/ibd/izz072.

    Article  PubMed  Google Scholar 

  12. Krauthammer A, Tzivinikos C, Assa A, Miele E, Strisciuglio C, Urlep D, Serban ED, Singh A, Winter HS, Russell RK, Hojsak I, Malham M, Navas-López VM, Croft NM, Lee HM, Ledder O, Shamasneh I, Hussey S, Huynh HQ, Wine E, Shah N, Sladek M, de Meij TG, Romano C, Dipasquale V, Lionetti P, Afzal NA, Aloi M, Lee K, Martín-de-Carpi J, Yerushalmy-Feler A, Subramanian S, Weiss B, Shouval DS. Long-term outcomes of paediatric patients admitted with acute severe colitis—a multicentre study from the paediatric IBD Porto group of ESPGHAN. J Crohns Colitis. 2019;13(12):1518–26. https://doi.org/10.1093/ecco-jcc/jjz092.

    Article  PubMed  Google Scholar 

  13. Lamousé-Smith ES, Weber S, Rossi RF, Neinstedt LJ, Mosammaparast N, Sandora TJ, et al. Polymerase chain reaction test for Clostridium difficile toxin B gene reveals similar prevalence rates in children with and without inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2013;57(3):293–7.

    PubMed  Google Scholar 

  14. Pascarella F, Martinelli M, Miele E, Del Pezzo M, Roscetto E, Staiano A. Impact of Clostridium difficile infection on pediatric inflammatory bowel disease. J Pediatr. 2009;154(6):854–8.

    PubMed  Google Scholar 

  15. Ananthakrishnan AN, McGinley EL, Binion DG. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut. 2008;57(2):205–10.

    CAS  PubMed  Google Scholar 

  16. Negrón ME, Rezaie A, Barkema HW, Rioux K, De Buck J, Checkley S, et al. Ulcerative colitis patients with clostridium difficile are at increased risk of death, colectomy, and postoperative complications: a population-based inception cohort study. Am J Gastroenterol. 2016;111(5):691–704.

    PubMed  Google Scholar 

  17. Livshits A, Fisher D, Hadas I, Bdolah-Abram T, Mack D, Hyams J, et al. Abdominal X-ray in pediatric acute severe colitis and radiographic predictors of response to intravenous steroids. J Pediatr Gastroenterol Nutr. 2016;62(2):259–63.

    CAS  PubMed  Google Scholar 

  18. McIntyre PB, Powell-Tuck J, Wood SR, Lennard-Jones JE, Lerebours E, Hecketsweiler P, et al. Controlled trial of bowel rest in the treatment of severe acute colitis. Gut. 1986;27(5):481–5.

    CAS  PubMed  PubMed Central  Google Scholar 

  19. Mantzaris GJ, Petraki K, Archavlis E, Amberiadis P, Kourtessas D, Christidou A, et al. A prospective randomized controlled trial of intravenous ciprofloxacin as an adjunct to corticosteroids in acute, severe ulcerative colitis. Scand J Gastroenterol. 2001;36(9):971–4.

    CAS  PubMed  Google Scholar 

  20. Chapman RW, Selby WS, Jewell DP. Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis. Gut. 1986;27(10):1210–2.

    CAS  PubMed  PubMed Central  Google Scholar 

  21. Turner D, Bishai J, Reshef L, Abitbol G, Focht G, Marcus D, Ledder O, Lev-Tzion R, Orlanski-Meyer E, Yerushalmi B, Aloi M, Griffiths AM, Albenberg L, Kolho K-L, Assa A, Cohen S, Gophna U, Vlamakis H, Lurz E, Levine A. Antibiotic cocktail for pediatric acute severe colitis and the microbiome: the PRASCO randomized controlled trial. Inflamm Bowel Dis. 2020;26(11):1733–42. https://doi.org/10.1093/ibd/izz298.

    Article  PubMed  Google Scholar 

  22. Mishra S, Mandavdhare HS, Singh H, Choudhury A, Shah J, Ram S, Kalsi D, Samanta J, Prasad KK, Sharma AK, Dutta U, Sharma V. Adjuvant use of combination of antibiotics in acute severe ulcerative colitis: a placebo controlled randomized trial. Expert Rev Anti-Infect Ther. 2021;19(7):949–55. https://doi.org/10.1080/14787210.2021.1856656.

    Article  CAS  PubMed  Google Scholar 

  23. Nylund CM, Goudie A, Garza JM, Crouch G, Denson LA. Venous thrombotic events in hospitalized children and adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2013;56(5):485–91.

    PubMed  Google Scholar 

  24. Zitomersky NL, Verhave M, Trenor CC 3rd. Thrombosis and inflammatory bowel disease: a call for improved awareness and prevention. Inflamm Bowel Dis. 2011;17(1):458–70.

    PubMed  Google Scholar 

  25. Lazzerini M, Bramuzzo M, Maschio M, Martelossi S, Ventura A. Thromboembolism in pediatric inflammatory bowel disease: systematic review. Inflamm Bowel Dis. 2011;17(10):2174–83.

    PubMed  Google Scholar 

  26. Zitomersky NL, Levine AE, Atkinson BJ, Harney KM, Verhave M, Bousvaros A, et al. Risk factors, morbidity, and treatment of thrombosis in children and young adults with active inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2013;57(3):343–7.

    CAS  PubMed  Google Scholar 

  27. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J. 1955;2(4947):1041–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  28. Turner D, Walsh CM, Steinhart AH, Griffiths AM. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol. 2007;5(1):103–10.

    CAS  PubMed  Google Scholar 

  29. Choshen S, Finnamore H, Auth MK, Bdolah-Abram T, Shteyer E, Mack D, et al. Corticosteroid dosing in pediatric acute severe ulcerative colitis: a propensity score analysis. J Pediatr Gastroenterol Nutr. 2016;63:58–64.

    CAS  PubMed  Google Scholar 

  30. Turner D, Kolho KL, Mack DR, Raivio T, Leleiko N, Crandall W, et al. Glucocorticoid bioactivity does not predict response to steroid therapy in severe pediatric ulcerative colitis. Inflamm Bowel Dis. 2010;16(3):469–73.

    PubMed  Google Scholar 

  31. Turner D, Griffiths AM. Acute severe ulcerative colitis in children: a systematic review. Inflamm Bowel Dis. 2011;17(1):440–9.

    PubMed  Google Scholar 

  32. Wine E, Mack DR, Hyams J, Otley AR, Markowitz J, Crandall WV, et al. Interleukin-6 is associated with steroid resistance and reflects disease activity in severe pediatric ulcerative colitis. J Crohns Colitis. 2013;7(11):916–22.

    PubMed  Google Scholar 

  33. Michail S, Durbin M, Turner D, Griffiths AM, Mack DR, Hyams J, et al. Alterations in the gut microbiome of children with severe ulcerative colitis. Inflamm Bowel Dis. 2012;18(10):1799–808.

    PubMed  Google Scholar 

  34. Ayre K, Warren BF, Jeffery K, Travis SP. The role of CMV in steroid-resistant ulcerative colitis: a systematic review. J Crohns Colitis. 2009;3(3):141–8.

    PubMed  Google Scholar 

  35. Rahier JF, Magro F, Abreu C, Armuzzi A, Ben-Horin S, Chowers Y, et al. European Crohn’s and Colitis Organisation (ECCO). Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2014;8(6):443–68.

    CAS  PubMed  Google Scholar 

  36. Cohen S, Martinez-Vinson C, Aloi M, Turner D, Assa A, de Ridder L, Wolters VM, de Meij T, Alvisi P, Bronsky J, Kopylov U, Pediatric IBD Porto Group of ESPGHAN. CMV infection in pediatric severe ulcerative colitis—a multicenter study from the pediatric IBD Porto Group of ESPGHAN. Pediatr Infect Dis J. 2018;37(3):197–201. 01.03.2018.

    PubMed  Google Scholar 

  37. Hyams J, Damaraju L, Blank M, Johanns J, Guzzo C, Winter HS, et al. T72 Study Group. Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis. Clin Gastroenterol Hepatol. 2012;10(4):391–9.

    CAS  PubMed  Google Scholar 

  38. Aloi M, D’Arcangelo G, Capponi M, Nuti F, Vassallo F, Civitelli F, et al. Managing paediatric acute severe ulcerative colitis according to the 2011 ECCO-ESPGHAN guidelines: efficacy of infliximab as a rescue therapy. Dig Liver Dis. 2015;47(6):455–9.

    CAS  PubMed  Google Scholar 

  39. Adedokun OJ, Xu Z, Padgett L, Blank M, Johanns J, Griffiths A, et al. Pharmacokinetics of infliximab in children with moderate-to-severe ulcerative colitis: results from a randomized, multicenter, open-label, phase 3 study. Inflamm Bowel Dis. 2013;19(13):2753–62.

    PubMed  Google Scholar 

  40. Rosen MJ, Minar P, Vinks AA. Review article: applying pharmacokinetics to optimise dosing of anti-TNF biologics in acute severe ulcerative colitis. Aliment Pharmacol Ther. 2015;41(11):1094–103.

    CAS  PubMed  PubMed Central  Google Scholar 

  41. Shapiro JM, Subedi S, Machan JT, Cerezo CS, Ross AM, Shalon LB, et al. Durability of infliximab is associated with disease extent in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2016;62(6):867–72.

    CAS  PubMed  Google Scholar 

  42. Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994;330(26):1841–5.

    CAS  PubMed  Google Scholar 

  43. Shibolet O, Regushevskaya E, Brezis M, Soares-Weiser K. Cyclosporine A for induction of remission in severe ulcerative colitis. Cochrane Database Syst Rev. 2005;1:CD004277.

    Google Scholar 

  44. Okafor PN, Nunes DP, Farraye FA. Pneumocystis jiroveci pneumonia in inflammatory bowel disease: when should prophylaxis be considered? Inflamm Bowel Dis. 2013;19(8):1764–71.

    PubMed  Google Scholar 

  45. Watson S, Pensabene L, Mitchell P, Bousvaros A. Outcomes and adverse events in children and young adults undergoing tacrolimus therapy for steroid-refractory colitis. Inflamm Bowel Dis. 2011;17(1):22–9.

    PubMed  Google Scholar 

  46. Ziring DA, Wu SS, Mow WS, Martín MG, Mehra M, Ament ME. Oral tacrolimus for steroid-dependent and steroid-resistant ulcerative colitis in children. J Pediatr Gastroenterol Nutr. 2007;45(3):306–11.

    CAS  PubMed  Google Scholar 

  47. Navas-López VM, Blasco Alonso J, Serrano Nieto MJ, Girón Fernández-Crehuet F, Argos Rodriguez MD, Sierra SC. Oral tacrolimus for pediatric steroid-resistant ulcerative colitis. J Crohns Colitis. 2014;8(1):64–9.

    PubMed  Google Scholar 

  48. Laharie D, Bourreille A, Branche J, Allez M, Bouhnik Y, Filippi J, et al. Groupe d’Etudes Thérapeutiques des Affections Inflammatoires Digestives. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet. 2012;380(9857):1909–15.

    CAS  PubMed  Google Scholar 

  49. Narula N, Marshall JK, Colombel JF, Leontiadis GI, Williams JG, Muqtadir Z, et al. Systematic review and meta-analysis: infliximab or cyclosporine as rescue therapy in patients with severe ulcerative colitis refractory to steroids. Am J Gastroenterol. 2016;111(4):477–91.

    CAS  PubMed  Google Scholar 

  50. Minami N, Yoshino T, Matsuura M, Koshikawa Y, Yamada S, Toyonaga T, et al. Tacrolimus or infliximab for severe ulcerative colitis: short-term and long-term data from a retrospective observational study. BMJ Open Gastroenterol. 2015;2(1):e000021.

    PubMed  PubMed Central  Google Scholar 

  51. Endo K, Onodera M, Shiga H, Kuroha M, Kimura T, Hiramoto K, et al. A comparison of short- and long-term therapeutic outcomes of infliximab-versus tacrolimus-based strategies for steroid-refractory ulcerative colitis. Gastroenterol Res Pract. 2016;2016:3162595.

    PubMed  PubMed Central  Google Scholar 

  52. Maser EA, Deconda D, Lichtiger S, Ullman T, Present DH, Kornbluth A. Cyclosporine and infliximab as rescue therapy for each other in patients with steroid-refractory ulcerative colitis. Clin Gastroenterol Hepatol. 2008;6(10):1112–6.

    CAS  PubMed  Google Scholar 

  53. Leblanc S, Allez M, Seksik P, Flourié B, Peeters H, Dupas JL, et al. GETAID. Successive treatment with cyclosporine and infliximab in steroid-refractory ulcerative colitis. Am J Gastroenterol. 2011;106(4):771–7.

    CAS  PubMed  Google Scholar 

  54. Narula N, Fine M, Colombel JF, Marshall JK, Reinisch W. Systematic review: sequential rescue therapy in severe ulcerative colitis: do the benefits outweigh the risks? Inflamm Bowel Dis. 2015;21(7):1683–94.

    PubMed  Google Scholar 

  55. Ryan DP, Doody DP. Restorative proctocolectomy with and without protective ileostomy in a pediatric population. J Pediatr Surg. 2011;46(1):200–3.

    PubMed  Google Scholar 

  56. Ferrante M, D’Hoore A, Vermeire S, Declerck S, Noman M, Van Assche G, et al. Corticosteroids but not infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis. Inflamm Bowel Dis. 2009;15(7):1062–70.

    CAS  PubMed  Google Scholar 

  57. Weston-Petrides GK, Lovegrove RE, Tilney HS, Heriot AG, Nicholls RJ, Mortensen NJ, et al. Comparison of outcomes after restorative proctocolectomy with or without defunctioning ileostomy. Arch Surg. 2008;143(4):406–12.

    PubMed  Google Scholar 

  58. Schaufler C, Lerer T, Campbell B, Weiss R, Cohen J, Sayej W, et al. Preoperative immunosuppression is not associated with increased postoperative complications following colectomy in children with colitis. J Pediatr Gastroenterol Nutr. 2012;55(4):421–4.

    CAS  PubMed  Google Scholar 

  59. Rajaratnam SG, Eglinton TW, Hider P, Fearnhead NS. Impact of ileal pouch-anal anastomosis on female fertility: meta-analysis and systematic review. Int J Color Dis. 2011;26(11):1365–74.

    Google Scholar 

  60. Melmed GY, Fleshner PR, Bardakcioglu O, Ippoliti A, Vasiliauskas EA, Papadakis KA, et al. Family history and serology predict Crohn’s disease after ileal pouch-anal anastomosis for ulcerative colitis. Dis Colon Rectum. 2008;51(1):100–8.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Harvard Medical School, Pediatric Gastroenterology, MassGeneral Hospital for Children, Boston, MA, USA

    Jess L. Kaplan

  2. Harvard Medical School, Pediatric IBD Program, MassGeneral Hospital for Children, Boston, MA, USA

    Harland S. Winter

Authors
  1. Jess L. Kaplan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Harland S. Winter
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Jess L. Kaplan or Harland S. Winter .

Editor information

Editors and Affiliations

  1. Division of GI, Hepatology & Nutrition, Children’s Hospital of Philadelphia, Philadelphia, PA, USA

    Petar Mamula

  2. Division of GI, Hepatology & Nutrition, Children’s Hospital of Philadelphia, Philadelphia, PA, USA

    Judith R. Kelsen

  3. Division of GI, Hepatology & Nutrition, Children’s Hospital of Philadelphia, Philadelphia, PA, USA

    Andrew B. Grossman

  4. Division of GI, Hepatology & Nutrition, Children’s Hospital of Philadelphia, Philadelphia, PA, USA

    Robert N. Baldassano

  5. Division of Pediatric Gastroenterology, Prisma Health Children’s Hospital—Upstate, Greenville, SC, USA

    Jonathan E. Markowitz

Rights and permissions

Reprints and permissions

Copyright information

© 2023 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Kaplan, J.L., Winter, H.S. (2023). Treatment of Acute Severe Ulcerative Colitis. In: Mamula, P., Kelsen, J.R., Grossman, A.B., Baldassano, R.N., Markowitz, J.E. (eds) Pediatric Inflammatory Bowel Disease. Springer, Cham. https://doi.org/10.1007/978-3-031-14744-9_36

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-14744-9_36

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-14743-2

  • Online ISBN: 978-3-031-14744-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation